On Thursday, Shares of Netflix, Inc. (NASDAQ:NFLX), gained 2.67% to $123.73.
U.S. broadcast TV network NBC is unlikely to extend its binge-watching experiment for the second season of drama “Aquarius, the head of entertainment at the Comcast-owned network said on Thursday, though he would not rule out trying the approach for other series, according to Reuters.
The success of Netflix Inc, with 65 million global subscribers, is pressuring traditional TV networks to try new approaches as they compete with online outlets for viewers, especially younger audiences who watch video on mobile devices. Reuters Reports
In a first for a broadcast network, NBC in May put all 13 “Aquarius” episodes online for four weeks right after the premiere aired on TV. The move was similar to Netflix’s strategy of releasing entire seasons at once for binge watching. Reuters added.
Netflix, Inc., an Internet television network, engages in the Internet delivery of TV shows and movies directly on TVs, computers, and mobile devices in the United States and internationally.
Shares of Novavax, Inc. (NASDAQ:NVAX), declined -1.54% to $13.44, during its last trading session.
Novavax Inc. surged the most in six years after its vaccine assisted elderly patients in a mid-stage study fend off a potentially lethal respiratory virus, according to Bloomberg.
The vaccine reduced the risk of the disease associated with lower respiratory infection by 46 percent when contrast with a placebo in 1,600 patients aged 60 and older, according to a statement late Monday. The shares rose 24 percent to $13.89 at the close in New York on Tuesday, giving Novavax a market value of $3.75 billion. Bloomberg Reports
There are presently no approved vaccines to prevent respiratory syncytial virus, or RSV, which kills about 14,000 American adults over 65 every year, according to the U.S. Centers for Disease Control and Prevention. About 4.9 percent of participants who received the placebo showed symptoms of RSV, the study found. Treating RSV in the elderly is Novavax’s largest opportunity, according to Joel Beatty, an analyst at Citigroup Inc. Bloomberg said.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
Finally, ONEOK Inc. (NYSE:OKE), ended its last trade with -3.76% loss, and closed at $36.34.
ONEOK declared an offering to sell $500 million of senior notes. The notes will be issued under ONEOK’s existing shelf registration statement formerly filed with the U.S. Securities and Exchange Commission.
ONEOK anticipates to use the net proceeds from this offering and cash on hand to purchase additional common units from ONEOK Partners, L.P. (OKS) in a private placement. Funds managed by Kayne Anderson Capital Advisors, L.P. have agreed to purchase $100 million of common units from ONEOK Partners concurrently with ONEOK’s purchase. Following the common units purchases, ONEOK, which is the sole general partner of ONEOK Partners, will enhance its ownership percentage to 41.2 percent from 36.8 percent.
The sole book-running manager for the offering is Citigroup.
ONEOK, Inc., through its general partner interests in ONEOK Partners, L.P., engages in the gathering, processing, storage, and transportation of natural gas in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
